Burst CME™: Elevating Care in the Management of IgA Nephropathy (IgAN) Nursing Track

Activity Overview

In part I, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss the current standard of care for the treatment of IgAN, highlighting information from the most recent Kidney Disease: Improving Global Outcomes guidelines.

In part II, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss endothelin-targeting therapies for the treatment of IgAN.

In part III, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss BAFF- and APRIL-targeting therapies for the treatment of IgAN.

In part IV, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss anti-CD38 therapies for IgAN.

In part V, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss complement-inhibiting therapies for IgAN.

In part VI, faculty experts Jonathan Barratt, PhD, FRCP; and Richard Lafayette, MD; discuss the treatment of IgAN, focusing on the integration of new and emerging agents to optimize treatment plans.

Target Audience

This educational activity is directed toward nephrologists, nephrology nurses, nurse practitioners, physician assistants, registered nurses, and other health care practitioners involved in the care of patients with IgAN.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review pathophysiological mechanisms of IgAN
• Analyze recent efficacy and safety trial data on new and emerging treatments for IgAN
• Design individualized treatment plans for patients with IgAN

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Additional Disclaimers

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.

In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.

Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.